In 2011, brentuximab vedotin (developed by Seattle Genetics) consists of a chimeric monoclonal antibody linked with a peptide-based (valine-citrulline) cleavable linker targeted to CD30 (also known as TNFRSF8) cell surface protein was launched for the treatment of relapsed or refractory Hodgkin lymphoma and in 2013, ado-trastuzumab emtansine (also known as T-DM1, developed by Roche) targeting human epidermal growth factor receptor 2 (HER2; also known as ERBB2, Kadcyla), was commercialized for the treatment of solid tumors (33–36; 37). The gene discussed is ERBB2; the disease is Hodgkins lymphoma.